Print

Artificial intelligence in ocular medicine: Seeing into the future

ARVO Online Education event

ARVOLearnIn April 2018, the FDA approved the first Artificial Intelligence (AI) enabled device to detect “more than mild diabetic retinopathy.” Globally, additional AI devices have been approved for use in ophthalmic clinics and more are in development. Despite these advances, many clinicians and researchers are unaware of how the technology works, what technology has been approved for clinical use or is in the development pipeline and how to integrate these potential technologies into their research or clinical practice. Researchers face many challenges when developing these algorithms and moving the resulting products from the lab to the clinic.

This event will address these topics and other approaches and uses for AI in ocular medicine through an online educational event that will include a series of live and recorded presentations and panel discussions, an AI technology video showcase and discussion forums. Registration will open in March.

  • Experience live and/or recorded panel discussions. Topics include current and potential uses of AI in ophthalmic care, common challenges associated with developing AI algorithms and moving AI technology from the lab to the clinic.
  • Discover current and emerging uses of AI. The AI technology showcase includes short video presentations describing products approved for use and those in-development.
  • Learn at your own pace. Select from a series of recorded presentations given by key leaders in this field on everything from what is AI, what can it do, how is it developed, and more.
  • Interact with your colleagues. Discussion forums enable you to ask questions and learn from your colleagues.
Who should attend?
  • Ophthalmologists, optometrists and others involved with clinical care who are interested in learning more about how AI works and the current and potential opportunities to integrate AI into their practice.
  • Researchers seeking to overcome the challenges of AI algorithm development and deployment.
Event planning committee
  • Committee Chair: Rajat N Agrawal, MD MS, CEO Retinal Global
  • Siamak Yousefi, PhD, Director of the Data Mining and Machine Learning (DM2L) Laboratory, University of Tennessee Health Science Center
  • Michael David Abramoff, MD, PhD, FARVO, Ophthalmology & Visual Sciences, University of Iowa Hospitals & Clinics, ID
  • Michael F Chiang, MD, Ophthalmology and Medical Informatics, Oregon Health & Science University 
  • Susan C Orr, OD, Chief Executive Officer, Notal Vision
  • Arthur H Shedden, Jr., MBA, MD, Senior Safety Officer, Johnson & Johnson Vision Care, Inc.
  • Daniel SW Ting, MD, PhD, Singapore National Eye Centre

Call for participation in the AI Technology Showcase

Applications are now being accepted for participation in the AI technology showcase portion of this online event. Participation will be via a short video submission (details outlined below). Applicants are asked to complete a brief application form that will ask for a description of the technology/product and a list of related publications. It only takes a few minutes to apply. The organizers are committed to a geographically diverse program. There is no cost to participate in the technology showcase and ARVO membership is not required for submission. Technologies that are currently approved or are nearing approval for use in the clinic either by the FDA or an international equivalent are highly desired.

Preparing your application

The application form will ask you to provide: a name and description of the product, the ocular disease(s) asssessed with the product, the primary status of the product (prototype, pre/clinical trial, approval pending, approved), where approval has been received or is being sought  and a list of publications related to the product. 

Application timeline
  • Applications can be submitted starting on Monday, Feb. 4 and ending on Thursday, Feb. 28.
  • Acceptance notifications will be sent no later than Monday, March 25.
  • Video submissions will be accepted between March 25 and April 22.
Video submission specifications
  • It should describe the science behind the technology and its current and/or potential uses in ophthalmic clinical care and/or research.
  • It should not reference, in any direct or indirect way, comparisons to any competing interest(s).
  • It should be approximately five to seven minutes in length and presented in English. Subtitles in another language are acceptable.
  • It may include contact details, so attendees can follow-up.
  • It must be of acceptable quality as no editing will be conducted.
  • Minimum technology specifications: File format (.mp4) Video encoding: H.264, MPEG-4 AVC, Resolution: 1280x720